Skip to main content

ACR 2023 – Day 4 Report

The last day at ACR23 was a ghost town as most left, largely because there was limited programming on the fourth and final day. The main attraction on Day 4 was the late-breaking abstract – oral presentations.  Here’s a list of the late breakers; below, I provide commentary on the ones that caught my attention.

Wednesday, November 15, 2023 – LATE-BREAKING ABSTRACTS

L17 - Safety, Tolerability, and Exploratory Efficacy of Afimetoran, a TLR7/8 Inhibitor, in Patients with Cutaneous Lupus Erythematosus: A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study. Fareeda Hosein, MD, MBA

  • Toll-Like Receptor Targeting in Lupus (Abstract L17).  This late breaker showed the safety and efficacy of Afimetoran, an oral TLR7/8 inhibitor, in an early phase Ib trial performed in 13 ANA+, SLE patients with biopsy proven cutaneous LE (CLE and a CLASI-A score > 6.  Discoid or SCLE was present in 11 patients and six had acute LE skin disease. There were no deaths or serious AEs or serious infectious events. Placebo patients (n=5) had no response, while those on Afimetoran (n=8) had a significant reduction in CLASI-A score by week 4, through till week 20. Improvement was associated with a reduction in interferon signature as well. This is a first in class, novel inhibitor of TLRs thought to be involved in alpha interferon generation. 

L15 - AR882, an Efficacious and Selective URAT1 Inhibitor for Patients with Chronic Gouty Arthritis and Subcutaneous Tophi: Results from a Global, Prospective, Proof-of-Concept Trial Using Dual Energy Computed Tomography  Robert T. Keenan, MD, MPH

L16 - Withdrawal of Immunosuppressant and Low-dose Steroids in IgG4-RD Patients with Stable Disease (WInS IgG4-RD): An Investigator-initiated, Multi-center, Open-label, Randomized Controlled Trial.  Linyi Peng

L18 - Immune-metabolic Heterogeneity and Clinical Implications in Primary Sjogren's Syndrome Revealed by Molecular Classification of Salivary Glands. Huji Xu.

L19 - A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks. David Hunter, PhD, MBBS, FRACP

:L20 - Telitacicept, a Human Recombinant Fusion Protein Targeting and Neutralizing B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Rheumatoid Arthritis (RA) Patients with an Inadequate Response to Methotrexate (MTX): A Randomized, Double-Blind, Phase 3 Study. Qing Zuraw, MD, MPH, MBA

  • B cell Targeting with Telitacicept in RA (L20).  Wang et al presented results of a phase III trial of telitacicept (TELI), a fusion protein that targets both BlyS and APRIL on B cells. This was previously studied in lupus and Sjogrens with reported success. In this placebo controlled trial, MTX-IR patients were given either PBO (n 116) or TELI (n 360) with the primary endpoint being ACR20 at week 24.  Roughly 90% completed the blinded portion of the trial. TELI demonstrated a significantly better ACR Response (60% vs. 27%; p> 0.001) at week 24, Similarly ACR 50 (21% vs. 6%), ACR70 and radiographic (mTSS) outcomes were superior for TELI patients. There were serious infections (~2-3%) with both treatment groups. This drug is commercially available only in China and these results were limited to a Chinese RA population.  Further study in multinational cohorts is needed.


If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

The author has received compensation as an advisor or consultant on this subject